Company / Free Cash Flow
Intellia Therapeutics, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$395.9M
FY2025
5-year range
-$408.1M / -$237.8M
FY2021-FY2025
Trend
-11.6%
vs FY2024
Sector context
#143 of 145
Health Care
What the data says
Among 145 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 1% for free cash flow. Free Cash Flow has fluctuated over the past 10 years, ranging from -$408M in FY2023 to $30M in FY2016.
Based on SEC 10-K filings.
-$396M in FY2025.
Improved from -$408M to -$396M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 145This company -$395.9M Sector average $770.9M
▼
-151.4% below sector average
Key checks
Key Insights
- In FY2025, free cash flow decreased 11.6% year-over-year.
- Ranks #143 out of 145 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2016.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$395.9M | -11.6% |
| FY2024 | -$354.7M | +13.1% |
| FY2023 | -$408.1M | -17.7% |
| FY2022 | -$346.8M | -45.9% |
| FY2021 | -$237.8M | -344.5% |
| FY2020 | -$53.5M | +51.4% |
| FY2019 | -$110.0M | -62.7% |
| FY2018 | -$67.6M | +10.3% |
| FY2017 | -$75.4M | -351.7% |
| FY2016 | $29.9M | +793.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026